Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Maxmoeon Oct 14, 2024 12:01pm
77 Views
Post# 36265241

RE:RE:In normal market reaction the SP should have gone up

RE:RE:In normal market reaction the SP should have gone up
PWIB123 wrote: They alienated and abandoned the investors who would have driven the price up today.  The earnings report was actually really good.  The share price is a reflection of the leadership team's past decisions.  I do appreciate the turnaround in profitability, which should be enough to drive share price appreciation.  Clearly there wasn't huge success in the patients that completed the TH-1902 trial.  I'm guessing they'll have some parts and pieces that look good and have potential in combination therapy, but no standout results on their own.  If there was, I think we would have heard about that today.  I am pleased to hear them say there were no DLT's.  That's a positive improvement.

My observation over the decades with this sector is "good news travels first class". It always leaks out. Mediocre results are delayed or buried. It was clearly not the blockbuster results we always hope for but too early to draw conclusions for me. Patience with the patients. Financial discipline is not a "given" for this sector, so it's a very good thing here. 
<< Previous
Bullboard Posts
Next >>